FDA Plans For Private-Payer Meetings Ahead, But Roadblocks Remain
This article was originally published in The Gray Sheet
Executive Summary
FDA’s device center is recruiting private payers to meet with manufacturers during the pre-submission process to hasten reimbursement. But some experts believe the effort may be hobbled by a lack of common interests.
You may also be interested in...
Medicare Will Look To Informal Pathways For Faster Medtech Reimbursement
The US Centers for Medicare and Medicaid Services has withdrawn efforts on a proposed rule to offer faster Medicare reimbursement to novel devices, but the agency still plans to work on different approaches to provide "timely patient access" to device innovations, a spokeswoman said. AdvaMed says it is disappointed by CMS's decision to withdraw the rule after a 10-month review by the Office of Management and Budget.
Payers Want Access To US FDA's Pre-Submission Meetings
As sponsors push for more access to physicians, payers hope to be able to gather more pre-approval information about drugs – like they now can with devices – for budgeting and patient access.
Bringing Private Payers To The Regulatory Table: FDA Reaches Out To Insurers
The agency's device center put out a request to health insurers to make themselves available to participate in FDA pre-submission meetings so that device firms, particularly start-ups, can better understand data expectations for coverage while companies are still designing studies to support FDA approval.